Shopping Cart
- Remove All
Your shopping cart is currently empty
Orilanolimab (SYNT001) is a humanized, de-immunized monoclonal antibody that inhibits the FcRn-IgG interaction, disrupting IgG homeostasis and impeding FcRn-mediated adaptive immune responses and related innate and adaptive immunity pathways [1] [2].
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $456 | 2-4 weeks | |
| 5 mg | $1,180 | 2-4 weeks | |
| 10 mg | $1,900 | 2-4 weeks |
| Description | Orilanolimab (SYNT001) is a humanized, de-immunized monoclonal antibody that inhibits the FcRn-IgG interaction, disrupting IgG homeostasis and impeding FcRn-mediated adaptive immune responses and related innate and adaptive immunity pathways [1] [2]. |
| In vitro | Orilanolimab at concentrations of 10nM, 50nM, and 100nM administered over 48 hours, inhibits the production of CD11c+ IFN-γ in B2M TG/TG FCGRT TG/TG Fcgrt -/- mice [1]. |
| In vivo | Orilanolimab (20mg/kg; intravenous injection) significantly reduced plasma concentrations of HuLys11 in a murine model [1]. Dose-dependent and specific reductions in the circulating levels of IgG in cynomolgus monkeys were observed following orilanolimab administration (10-100 mg/kg; intravenous injection; every 5 weeks) [1]. |
| Synonyms | SYNT001 |
| Cas No. | 2066544-85-0 |
| Storage | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.